Loading patent…
AssigneeArcus Biosciences, Inc.
InventorsAmy Elizabeth Anderson, Devika Ashok, Daniel M. DiRenzo, Akshata R. Udyavar, Matthew J. Walters, Stephen W. Young
Estimating the term…
The present disclosure provides methods of treating a cancer in a subject having an established adenosine fingerprint. An established adenosine fingerprint includes assessing the blood concentration of one or more adenosine machinery proteins, assessing the enzymatic activity of one or more adenosine machinery proteins, and/or assessing the tumor expression level of adenosine machinery proteins. The methods disclosed herein include administering to said subjects a therapeutic agent selected from the group consisting of an agent targeting the extracellular production of adenosine, and an agent antagonizing the activation by adenosine of one of its receptors.
-78. (canceled)
A method of inhibiting or suppressing a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an adenosine A2a receptor (A2aR) or adenosine A2b receptor (A2bR) antagonist,
The method of claim 85, wherein the PD1 and/or PD-L1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, MEDI-0680, BGB-108, GB-226, PDR-001, mDX-400, SHR-1210, IBI-308, PF-06801591, atezolizumab, durvalumab, avelumab, BMS-936559, KD-033, CA-327, CA-170, ALN-PDL, TSR-042, and STI-1014.
Dependencies are inferred from the claim text.